UK: Phoney Pharmaceuticals

Last Updated: 2 April 2008
Article by Ed Harrison

A review of the trade in counterfeit medicines, and some associated Intellectual Property enforcement issues.

'A counterfeit medicine is one which is deliberately and fraudulently mislabeled with respect to identity and/or source. Counterfeiting can apply to both branded and generic products and counterfeit products may include products with the correct ingredients or with the wrong ingredients, without active ingredients, with insufficient active ingredients or with fake packaging.'

World Health Organisation definition.

Scale of the Problem

Counterfeit medicines are big business, both within the UK and on a worldwide basis. As with any black market activity, it is impossible to produce an accurate picture of the problem, but the numbers that are being suggested are terrifying. A recent estimate by the US Centre for Medicines in the Public Interest calculated that the value of worldwide sales in counterfeit drugs will reach US$ 75 billion by 2010, if the trade continues to expand at current rates.

The World Health Organisation (who) has historically reckoned that globally around 10% of all medicines are counterfeit. However, who has recently moved to a more geographically focused approach which suggests that in the more developed countries, the amount is more likely to be around 1% of the total market in medicines. However, the new approach highlights the fact that in less developed countries, the amount of counterfeit medicines is as high as 30% of the countries' entire trade in medicines. In relation to internet sales of drugs worldwide, the proportion of counterfeit products could be as high as 50%.

Human and Social Costs

The potential for damage to the individual is obvious. One of the worst counterfeit medicine cases encountered so far resulted in the deaths of around 2500 people in Niger in 1995, where around 50,000 people were inoculated with fake vaccines to treat meningitis. The vaccines had been supplied in good faith, but were sophisticated fakes.

Between 1995 and 1998 it is estimated that 119 children and infants died in Haiti and India after being treated with a cough syrup that contained diethylene glycol (a toxin also present in antifreeze).

On a larger scale, these individual cases can bring about a general distrust in drug based medicine. This is especially likely in less developed countries, where the potential for benefit to human health through use of such medicines is proportionately greater.

The nature of the counterfeit business (in whatever area) means that it is also commonly used by criminal gangs as a means of producing income, and also laundering money from other activities. A report from Interpol in 2003 also claimed that counterfeiting was becoming the preferred method of fundraising for terrorist groups and it is reckoned that a large percentage of the economy of North Korea is based on the export of counterfeit products (of all types).

If we also consider the more general social costs, the business of the medicine manufacturer is also being affected. Not only is the manufacturer losing out on income, but the reputation of the manufacturer and of the affected trade marks, is being severely damaged. Ultimately, this can result in economic damage that impairs continued investment in the development of new medicines and, in extreme cases, in the loss of jobs.

The Remedies

Technological Advances

Manufacturers continue to innovate in making it harder to copy genuine medicines. Technology is now being used to insert rfid devices into medicines, enabling them to be tracked and authenticated at any point. The longstanding concept of a watermark is evolving into the form of medicine 'dna', where lasers are used to pick up a unique infrared radiation emitted from the genuine medicines. The unique nature of the infrared frequencies can be used to distinguish genuine products from fakes.

However, such technological solutions only assist in countries where the technology exists and is affordable.

Distributorship Improvements

In the uk, following a recall of 120,000 packs of suspect Lipitor (used for lowering cholesterol) Pfizer Inc has taken the decision to transfer the distribution of their medicines to one company, in an attempt to cut out the number of companies involved in the movement of their medicines. Pfizer's own research estimated that as many as 20 to 30 different companies or individuals could be involved in handling the medicines between them leaving the manufacturing plant and being dispensed to the patient. Pfizer claims that the change was made to tighten the distribution chain and thereby reduce the chances of counterfeit products being able to enter the cycle.

Legal Enforcement

In most developed (and many undeveloped) countries, the legal tools exist that give the relevant authorities and the manufacturers the ability to take criminal legal action against not just those involved in producing counterfeit medicines, but also those who knowingly import, distribute, store or sell such products.

Many of the legal tools exist not as a result of general consumer protection laws, but increasingly because of the laws that protect Intellectual Property, and in particular Trade Marks.

Within Europe there is a generally harmonised approach to enforcement of registered trade marks, and legal changes over the last 10 to 15 years have produced an effective range of monitoring enforcement actions including:

  1. An EU wide monitoring service provided by customs authorities that watches for counterfeit products, following notification from the trade mark owner. There are also similar national monitoring schemes.
  2. National authorities responsible for general consumer protection have the power to bring criminal proceedings on the basis of trade mark laws. In the uk, the Trading Standards Office (TSO) has this function.
  3. National authorities responsible for regulating medicines also have the ability to bring criminal proceedings under trade mark laws. In the uk, the Medicines and Healthcare products Regulatory Agency (MHRA) has responsibility for this.

The legal backbone of this body of enforcement is found within the harmonised trade mark laws that apply around the eu. The laws all contain fairly strict sections which state that counterfeiting (and dealing in counterfeit products) is a criminal offence and which also specify that the local authorities have the power to enforce those sections of the laws. In the uk the relevant section in the Act actually obliges the authorities to act if counterfeiting is discovered.

The TSO has significant powers to deal with counterfeiters, and in many cases their authority to enter, search and seize property is similar to that of the police. In some more extreme counterfeiting cases, the police will also be directly involved in a raid on a suspected counterfeiter.

Manufacturers also have additional civil legal rights through the enforcement of Intellectual Property and in particular the infringement of registered trade marks. However in counterfeit cases such civil action is rarely appropriate, as it too slow to be effective in stopping most counterfeit activities quickly, and is expensive. However, manufacturers should, and do, actively assist the tso and mhra in taking criminal action.

Inherent within all of these legal systems is the fact that to take advantage of the majority of both civil and criminal legal actions, the trade mark for the counterfeited product must be a registered trade mark.

Most manufacturers of medicines have a sophisticated and active programme of trade mark registration, but it is important that this is maintained and kept up to date.

In a recent development, Interpol have announced that they are establishing a global database of ip crime, which would be available to law enforcement authorities, and which would feature information provided by other law enforcement authorities as well as manufacturers. It is intended to give an international framework to allow a swift and standardised means of reporting and dispersal of information relating to ip crime. In relation to counterfeit medicines, this resource may be particularly useful in identifying trends in the types of medicines being copied, and perhaps enabling the geographical source of the products to be discovered.

Education

There has been a recent flurry of schemes intended to promote awareness of the problem, and to educate those involved in how to deal with it. This ranges from advice to pharmacists provided by the mhra, advice to wholesalers provided by the British Association of Pharmaceutical Wholesalers (BAPW), through to international advice to national authorities by the International Medical Products Anti-counterfeiting Taskforce (IMPACT), which has recently been established by the who.

This need to educate has to be balanced with the need to avoid an unnecessary public distrust in the safety of all medicines. Indeed, it has been claimed, probably unfairly, that large pharmaceutical companies have purposefully not adopted a policy of publicising the problem precisely to avoid the negative implications of such an admission. However it is undeniable that education and public awareness will be a major factor in minimising the damage caused by counterfeit medicines.

The Future

Counterfeit medicines exist in a slightly separate sphere from other counterfeit products such as the entertainment and fashion industries, in that the reasons for stopping the counterfeiting are not simply legal or economic.

From a public health perspective the implications of failure to deal with the problem are obviously significantly more profound, not purely the death or damage to the health of an individual, but also the prospect of a general breakdown in trust between the ultimate consumer and those who work within the pharmaceutical industry and those who dispense and recommend those pharmaceutical treatments.

The pressure to get it right is great, and the onus lies firmly on the manufacturers and government bodies to make it as difficult as possible for counterfeiters to produce their goods in the first place and even more difficult to get those goods into the distribution and sales channels. It is perhaps unexpected to many that in most cases the legal tools for dealing with the problem stem from the seemingly obscure laws dealing with trade marks, but this is merely a return to the basic principle that a trade mark's main purpose is to guarantee a known quality and indicate a known origin. Whilst the trade mark laws have developed in sophistication to deal with an ever changing market, the fundamental principle of consumer protection remains constant.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Authors
 
In association with
Related Topics
 
Related Articles
 
Related Video
Up-coming Events Search
Tools
Print
Font Size:
Translation
Channels
Mondaq on Twitter
 
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
 
Email Address
Company Name
Password
Confirm Password
Position
Mondaq Topics -- Select your Interests
 Accounting
 Anti-trust
 Commercial
 Compliance
 Consumer
 Criminal
 Employment
 Energy
 Environment
 Family
 Finance
 Government
 Healthcare
 Immigration
 Insolvency
 Insurance
 International
 IP
 Law Performance
 Law Practice
 Litigation
 Media & IT
 Privacy
 Real Estate
 Strategy
 Tax
 Technology
 Transport
 Wealth Mgt
Regions
Africa
Asia
Asia Pacific
Australasia
Canada
Caribbean
Europe
European Union
Latin America
Middle East
U.K.
United States
Worldwide Updates
Registration (you must scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions

Mondaq.com (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of www.mondaq.com

To Use Mondaq.com you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.

Disclaimer

The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.

General

Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions